ASH 2023 | AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
Ibrahim Aldoss, MD, City of Hope, Duarte, CA, shares findings from the Phase II AUGMENT-101 trial (NCT04065399), which is evaluating the safety and efficacy of revumenib monotherapy in patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia, and was presented as a late-breaking abstract (LBA) at this year’s meeting. Dr Aldoss summarizes the overall response rate (ORR), complete response (CR) rate, and CR with partial hematologic recovery (CRh) rate observed. Revumenib demonstrated promising efficacy in this heavily pre-treated patient population, and the most common adverse events (AEs) were neutropenic fever, differentiation syndrome and QTc prolongation. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Jazz, Takeda, Sobi, Pfizer, Amgen, KiTE
Honoraria: Amgen
